Orchard Therapeutics Ltd., of London, won an FDA rare pediatric disease designation to OTL-101, its lead program for the treatment of adenosine deaminase severe combined immunodeficiency, a rare inherited disorder caused by mutations in the gene encoding for the enzyme adenosine deaminase that result in a severe deficiency in white blood cells and life-threatening infections.